Introduction
The goal is to identify the differentiating factors between adult stem cells and immune cells and to develop core platform technology for immune cell therapies that target cancer by researching their functions and a platform technology for anti-cancer antibody therapy and cancer diagnostics.
Research Areas
NK cell therapy
Hematopoietic stem cell (HSC) aging
Stem cell tech-based NK differentiation and production Cellular reprogramming
Human pluripotent stem cells
Head
Investigator
Name
Position
Tel / Email
Detail
Suk Ran Yoon
Associate Director
tel email Detail
Achievements
Molecular profiling of NK cell differentiation from stem cells
Development of immune therapy techniques utilizing NK cells
Molecular mechanism of HSC aging and stress
Stem cell technology-based NK cell production
Selected Publications
Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer.
Cell Death Dis. 8(3):e2682.Hee Gu Lee (Corresponding)
miR-150-mediated Foxo1 regulation programs CD8+ T cell differentiation.
Cell Rep. 20(11):2598-2611.Tae-Don Kim (Co-corresponding)
Upregulation of mitochondrial NAD+ levels impairs the clonogenicity of SSEA1+ glioblastoma tumor-initiating cells.
Exp Mol Med. 49(6):e344.Yee Sook Cho and Myung Jin Son (Co-corresponding)
Vitexin confers HSF-1 mediated autophagic cell death by activating JNK and ApoL1 in colorectal carcinoma cells.
Oncotarget. 8(68):112426-112441.Hee Gu Lee (Co-corresponding)
MicroRNA-150 modulates intracellular Ca 2+ levels in naive CD8+ T cells by targeting TMEM20.
Sci Rep. 7:2623.In Pyo Choi (Co-corresponding)
Suppressor of cytokine signaling 2 negatively regulates NK cell differentiation by inhibiting JAK2 activity.
Sci Rep. 7:46153.In Pyo Choi and Haiyoung Jung (Co-corresponding)
Schwann cell precursors from human pluripotent stem cells as a potential therapeutic target for myelin repair.
Stem Cell Reports. 8(6):1714-1726.Yee Sook Cho (Corresponding)
Biomarker discovery by modeling Behcet's disease with patient-specific human induced pluripotent stem cells.
Stem Cells Dev. 26(2):133-145.Yee Sook Cho (Corresponding)
Anti-cancer activity of novel TM4SF5-targeting antibodies through TM4SF5 neutralization and immune cell-mediated cytotoxicity.
Theranostics. 7(3):594-613.Semi Kim and Sang Jick Kim (Co-corresponding)
